Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avecho Biotechnology Ltd V.AVE


Primary Symbol: AVEFF

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.


OTCPK:AVEFF - Post by User

Bullboard Posts
Post by 93Darkhorse93on May 16, 2017 8:00pm
119 Views
Post# 26252549

April Revenue up over 1,000% to 16.8M!!!

April Revenue up over 1,000% to 16.8M!!!Wow! I refer you all to page 17 of the MD&A from Q1 report. For April 2017 the first month of Q2 revenue was 16.8M up from 1.5M or over 1,000%. If you annualize that revenue run rate for Q2 that is revenue of over 50M for Q2 revenues. They are going to easily do 200M in revenues for 2017, I have to revisit my model. I think my numbers may be way too conservative. They have quite the bullish story to tell tomorrow on the call.
Bullboard Posts